Liying Ma - Concepedia

Author

Liying Ma

Zhengzhou University ORCID

Also Known As

L Ma, L.-B. Ma, Li-Ying Ma, Li-ying Ma, LiYing Ma, Lixin Li, Liying Ma, Li‐Ying Ma, Ma Li-Ying, Ma, Liying

109

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Zhengzhou University Chinese Academy of Medical Sciences & Peking Union Medical College Ministry of Education of the People's Republic of China Hefei Institutes of Physical Science High Magnetic Field Laboratory

About

Liying Ma is an author at Zhengzhou University specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	2.1K
2	Natural Sciences	11	12	588
3	Biochemistry	5	5	231
4	Biomolecular Engineering	4	4	136
5	Biology	1	1	29

Liying Ma

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Identification of genomic alterations in oesophageal squamous cell cancer Yongmei Song, Lin Li, Yunwei Ou, Nature Tumor BiologySomatic VariantEsophageal CancerMedicinePathology	2014	1.1K
Design, Synthesis, and Structure–Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine–Thiourea Hybrids As Potent, Orally Active Antitumor Agents Liying Ma, Yi‐Chao Zheng, Saiqi Wang, Journal of Medicinal Chemistry	2015	156
Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents Liying Ma, L. Pang, Bo Wang, European Journal of Medicinal Chemistry Medicinal ChemistryNatural SciencesMedicineDiversity-oriented SynthesisOrganic Chemistry	2014	112
Design and synthesis of novel 1,2,3-triazole–pyrimidine–urea hybrids as potential anticancer agents Liying Ma, Bo Wang, L. Pang, Bioorganic & Medicinal Chemistry Letters Novel 1,2,3-Triazole–pyrimidine–urea HybridsMedicinal ChemistryNatural SciencesMedicineDiversity-oriented Synthesis	2015	98
Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer Zitong Zhao, Li Lin, Peina Du, Theranostics	2019	97
Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A) Zhonghua Li, Lina Ding, Zhongrui Li, Acta Pharmaceutica Sinica B	2019	78
Design, synthesis and biological evaluation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents Zhonghua Li, Dongxiao Yang, Peng Geng, European Journal of Medicinal Chemistry Combinatorial ChemistryMedicineAntiproliferative AgentsOrganic ChemistryBiological Evaluation	2016	71
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance Bo Wang, Liying Ma, Jing‐Quan Wang, Journal of Medicinal Chemistry Pharmaceutical ScienceP-glycoprotein-mediated Mutidrug ResistancePharmacotherapyDrug ResistanceMedicinal Chemistry	2018	70
Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway Saiqi Wang, Cong Wang, Liming Chang, Oncotarget	2016	67
CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis Jinghan Hua, Xiaolin Wang, Liying Ma, Molecular Cancer	2022	64

Page 1